# Treatment of Congenital Telangiectasia (Coat's Disease) With Open-label Anecortave Acetate (15mg.)

> **NCT00211315** · PHASE2 · COMPLETED · sponsor: **Manhattan Eye, Ear & Throat Hospital** · enrollment: 4 (actual)

## Conditions studied

- Coat's Disease

## Interventions

- **DRUG:** anecortave acetate

## Key facts

- **NCT ID:** NCT00211315
- **Lead sponsor:** Manhattan Eye, Ear & Throat Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-03
- **Primary completion:** —
- **Final completion:** 2007-03
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2012-10-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00211315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00211315, "Treatment of Congenital Telangiectasia (Coat's Disease) With Open-label Anecortave Acetate (15mg.)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00211315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*